SCHEMBL17847162

SCHEMBL17847162

CNc1cccc([N+](=O)[O-])c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.67
SMN1; SMN2 Q16637 3/20 0.60
TSHR P16473 3/20 0.60
POLB P06746 3/20 0.58
LMNA P02545 2/20 0.56
ALDH1A1 P00352 4/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
GAA P10253 2/20 0.52
NPC1 O15118 1/20 0.52
MAPK1 P28482 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
MAPT P10636 1/20 0.51
BLM P54132 1/20 0.49
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30198949 0.82 TDP1 (0.60) TDP1ALDH1A1GAANPC1MAPK1
SCHEMBL230874 0.82 TDP1 (0.60) TDP1ALDH1A1GAANPC1MAPK1
SCHEMBL472112 0.81 TDP1 (1.00) TDP1SMN1; SMN2TSHRPOLBLMNA
SCHEMBL7530234 0.80 TDP1 (0.60) TDP1SMN1; SMN2TSHRPOLBLMNA
SCHEMBL11551428 0.80 POLB (0.75) TDP1SMN1; SMN2TSHRPOLBLMNA
SCHEMBL7530232 0.80 TDP1 (0.60) TDP1SMN1; SMN2TSHRPOLBLMNA
SCHEMBL11325469 0.80 LMNA (0.83) TDP1SMN1; SMN2POLBLMNAALDH1A1
Hydrochloric Acid SCHEMBL28855008 0.80 TDP1 (0.58) TDP1ALDH1A1GAANPC1MAPK1
Water SCHEMBL27730559 0.80 TDP1 (0.58) TDP1ALDH1A1GAANPC1MAPK1
SCHEMBL11825436 0.79 GPR35 (0.64) TDP1SMN1; SMN2TSHRPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873914-A1 SELF-IMMOLATIVE SYSTEMS The Secretary of State for Defence (GB) 2021-09-08 EP disclosed
WO-2021104256-A1 HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 杭州华东医药集团新药研究院有限公司 2021-06-03 WO disclosed
US-10172814-B2 Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-08 US disclosed
US-20170354620-A1 SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-12-14 US disclosed
EP-3233802-A1 SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF Bayer Pharma Aktiengesellschaft (DE) 2017-10-25 EP disclosed
WO-2016097013-A1 SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172814-B2 Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof PTGER1, PTGES, PTGES3 TDP1 3966/4885SMN1; SMN2 3977/4885TSHR 4698/4885
US-20170354620-A1 SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF PTGER1, PTGES, PTGES3 TDP1 3966/4885SMN1; SMN2 3977/4885TSHR 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.